Session » Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 676

A Novel Role for the Psoriatic Arthritis Impact of Disease Questionnaire

9:00AM-11:00AM: Abstract Number: 691

A Service Evaluation of Reporting Standards of Computer Tomography Defined Sacroiliitis Suggestive of Axial Spondyloarthritis in Inflammatory Bowel Disease Patients Imaged for Non-Musculoskeletal Indications

9:00AM-11:00AM: Abstract Number: 672

Activation of NLRP3 Inflammasomes in Peripheral Blood Mononuclear Cells of Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 651

Analysis of the Different Value of Magnetic Resonance Imaging Changes in the Sacroiliac Joints for a Diagnosis of Axial Spondyloarthritis As Judged By Rheumatologists and Radiologists

9:00AM-11:00AM: Abstract Number: 649

Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on a Quick Quantitative CRP Assay Performs Similarly Well to ASDAS Based on Conventional CRP in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 703

Articular Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab

9:00AM-11:00AM: Abstract Number: 667

Assessment of Radiographic Sacroiliitis on Antero-Posterior Lumbar Radiographs As Compared to Conventional Pelvic Radiographs in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 689

Association of Kinesiophobia, Aerobic Exercise, Functional Impairment and Disease Activity of Patients with Rheumatoid Arthritis and Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 661

Bridging the Gap between Symptom Onset and Diagnosis in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 650

Can Disease Activity in Patients with Psoriatic Arthritis be Adequately Assessed By a Modified Disease Activity Index for Psoriatic Arthritis (DAPSA) Based on 28 Joints?

9:00AM-11:00AM: Abstract Number: 685

Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 673

Chronic Back Pain (CBP) in First Degree Relatives (FDRs) of Patient with Ankylosing Spondylitis (AS): Comparison with the US Population, HLA-B27 Frequency and Persistence of Symptoms over Time

9:00AM-11:00AM: Abstract Number: 687

Clinical Characteristics of Spondyloarthritis Patients in Japan in Comparison to Other Regions of the World

9:00AM-11:00AM: Abstract Number: 697

Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit

9:00AM-11:00AM: Abstract Number: 693

Combining Adalimumab with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®

9:00AM-11:00AM: Abstract Number: 694

Combining Etanercept with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®

9:00AM-11:00AM: Abstract Number: 659

Comparison of MRI and Conventional Radiography for Detection of Structural Changes Typical for Spa – Data from the Assessment of Spondyloarthritis International Society Cohort

9:00AM-11:00AM: Abstract Number: 658

Construct Validation of the Screening for Inflammatory Pain in the Lower Back Questionnaire: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort

9:00AM-11:00AM: Abstract Number: 641

Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 642

Cost of Illness Analysis before and after Initiation of Tumour Necrosis Factor α Inhibitors in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 674

Defining the Therapeutic Target in Psoriatic Arthritis: MDA Versus Dapsa

9:00AM-11:00AM: Abstract Number: 638

Diagnostic Delay and Associated Factors in Axial Spondyloarthritis across Europe. Results from the European Map of Axial Spondyloarthritis Survey

9:00AM-11:00AM: Abstract Number: 655

Diagnostic Performance of MRI Lesions in the Sacroiliac Joints According to Updated Assessments in Spondyloarthritis International Society Lesion Definitions: A Central Reader Assessment of MRI Scans from the Assessments in Spondyloarthritis Classification Cohort

9:00AM-11:00AM: Abstract Number: 698

Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 652

Disease Interception in Psoriasis Patients with Subclinical Joint Inflammation By Interleukin 17 Inhibition with Secukinumab – Data from a Prospective Open Label Study

9:00AM-11:00AM: Abstract Number: 646

Do Ethnicity, Degree of Family Relationship, and the Spondyloarthritis Subtype in Affected Relatives Influence the Association between a Positive Family History for Spondyloarthritis and HLA-B27 Carriership? Results from the Worldwide ASAS Cohort

9:00AM-11:00AM: Abstract Number: 702

Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 696

Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis

9:00AM-11:00AM: Abstract Number: 684

Efficacy of Ixekizumab in Different Phenotypes of Patients with Active Psoriatic Arthritis (PsA): Results from the Spirit Trials

9:00AM-11:00AM: Abstract Number: 657

First Validation of Consensus Definitions for MRI Lesions in the Sacroiliac Joint By the Assessments in Spondyloarthritis International Society MRI Group

9:00AM-11:00AM: Abstract Number: 686

Five-Year Efficacy and Safety of Apremilast Treatment in Subjects with Psa: A Pooled Analysis of the 3 Phase III Studies

9:00AM-11:00AM: Abstract Number: 669

High Prevalence of Axial Spondyloarthritis in Patients with Acute Anterior Uveitis and Chronic Back Pain – Preliminary Results of a Prospective Observational Study

9:00AM-11:00AM: Abstract Number: 637

How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives

9:00AM-11:00AM: Abstract Number: 681

Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor

9:00AM-11:00AM: Abstract Number: 700

Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial

9:00AM-11:00AM: Abstract Number: 665

Impact of Peripheral Manifestations on Patient-Reported Outcomes (PROs) and Treatment in Spondyloarthritis. Data from ASAS-Comospa

9:00AM-11:00AM: Abstract Number: 640

Increasing Rates of Arthroplasty for Psoriatic Arthritis in the United Kingdom between 1995 and 2010

9:00AM-11:00AM: Abstract Number: 666

Inflammation on MRI of the Sacroiliac Joints Is Highly Associated with Structural Damage in Axial Spondyloarthritis Patients in Clinical Practice: Data from the ASAS and DESIR Cohorts

9:00AM-11:00AM: Abstract Number: 644

Influence of Inflammation and Structural Damage on Global Functioning in Patients with Axial Spondyloarthritis – Using the ASAS Health Index in Routine Care

9:00AM-11:00AM: Abstract Number: 632

Interpretation of Symptoms Should Take into Account Gender in Psoriatic Arthritis: An Analysis of 451 Patients

9:00AM-11:00AM: Abstract Number: 639

Is a Primary Good Response to Nsaids Predictive of the Subsequent Response to the First TNF Inhibitor in Patients with Early Axial Spondyloarthritis ?

9:00AM-11:00AM: Abstract Number: 670

Low Rate of Spinal Radiographic Progression over 2 Years in Ankylosing Spondylitis Patients Treated with Secukinumab: A Historical Cohort Comparison

9:00AM-11:00AM: Abstract Number: 635

Measuring Spinal Mobility over Time in Early Axial Spondyloarthritis: Can We Do It Reliably?

9:00AM-11:00AM: Abstract Number: 654

MRI Lesion Definitions in Axial Spondyloarthritis: A Consensus Reappraisal from the Assessments in Spondyloarthritis International Society

9:00AM-11:00AM: Abstract Number: 701

Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment

9:00AM-11:00AM: Abstract Number: 699

New Onset/Recurrence of Inflammatory Arthralgia/Spondyloarthritis in Patients Treated with Vedolizumab for Intestinal Bowel Disease

9:00AM-11:00AM: Abstract Number: 682

Nonsteroidal Anti-Inflammatory Drug Use and Hypertension in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 648

Performance of an Online Self-Referral Questionnaire Compared to a Physician-Based Referral Approach to Identify Patients with a High Probability of Axial Spondyloarthritis: Results from the Optiref Study

9:00AM-11:00AM: Abstract Number: 664

Prevalence and Factors Associated with Peripheral Manifestations in Spondyloarthritis. an Ancillary Analysis of the ASAS-Comospa Study

9:00AM-11:00AM: Abstract Number: 660

Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data

9:00AM-11:00AM: Abstract Number: 668

Progression of Unilateral Grade 2 Sacroiliitis in a Psoriatic Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 675

Quantitative Ultrasound of the Calcaneus Has a Role to Play in Detecting Low Bone Mineral Density in Axial Spondyloarthropathy Patients

9:00AM-11:00AM: Abstract Number: 662

Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab for up to 3 Years

9:00AM-11:00AM: Abstract Number: 688

Real Life Analysis of a Latin America Tertiary Spondyloarthritis Single-Center: High Frequency of Peripheral Involvement and Use of Synthetic Dmard

9:00AM-11:00AM: Abstract Number: 645

Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany

9:00AM-11:00AM: Abstract Number: 663

Relative Contributions of Improvements in the Psoriasis Area and Severity Index (PASI) and Disease Activity Index for Psoriatic Arthritis (DAPSA) to Improvements in Quality of Life and Function in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 643

Remission in Psoriatic Arthritis: Definition and Predictors

9:00AM-11:00AM: Abstract Number: 636

Remission/Low Disease Activity Is a Reasonable Treatment Target in Psa: Results from a Routine Care European Cohort of Psa Patients Treated with Ustekinumab or TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 683

Spanish Validation of the Gepard Questionnaire for the Detection of Psoriatic Arthritis in Argentinean Patients with Psoriasis

9:00AM-11:00AM: Abstract Number: 634

Spinal Mobility Measures Allow Discrimination of Subgroups of Different Activity and Severity in Early Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 677

Structural Damage Characteristics of Patients with Ankylosing Spondylitis in China

9:00AM-11:00AM: Abstract Number: 690

Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 633

The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 692

TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 695

Tumor Necrosis Factor Inhibitor Persistence and Reasons for Discontinuation in US Veterans with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 678

Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy?

9:00AM-11:00AM: Abstract Number: 679

Ultrasonographic Research of the Relationship between Nail Disorders and Peripheral Arthritis or Enthesitis in Patients with Psoriasis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 680

Unmet Needs in the Treatment of Ankylosing Spondylitis. a Long-Term Observational Study from a Single University Center

9:00AM-11:00AM: Abstract Number: 647

Validation of a New Electronic Spinal Mobility Index for Patients with Axial Spondyloarthritis Based on Inertial Motion Unit (IMU) Sensors

9:00AM-11:00AM: Abstract Number: 653

Validation of Assessments in Spondyloarthritis International Society MRI Lesion Definitions in Axial Spondyloarthritis: Data from the Echography in Spondyloarthritis Cohort

9:00AM-11:00AM: Abstract Number: 671

Validation of the Rexspa (Reductive X-Ray Score for Psoriatic Arthritis) in an Argentinean Cohort of Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 656

What Is the Level of Agreement between Local and Central Readers in the Detection of Active and Structural MRI Lesions Typical of Axial Spondyloarthritis? Data from the Assessments in Spondyloarthritis Classification Cohort Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].